News on immunohistochemistry and other tissue-based testing methods.
With two FDA-cleared platforms available, the technology is drawing clinicians interested in reaping its near-term benefits while preparing for its future impact.
The center will initially use the system for prostate, and head and neck cancers and in the future will let LabCorp patients access Mount Sinai pathologists.
The digital pathology system can be used for primary diagnosis as a result of the 510(k) clearance, which followed a multicenter study conducted at five clinical sites.
The approach makes use of a microfluidic probe that allows researchers to more effectively collect data on the kinetics of antibody-target reactions.
The Boston-based company said it will use the funding in part to continue refining its artificial intelligence-powered pathology research platform.
